Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 2/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250959 | 0.87 | ULK1 (0.42) | ULK1NUDT1KDM4ECYP1A2LRRK2 | |
| SCHEMBL24092767 | 0.87 | ULK1 (0.42) | ULK1NUDT1KDM4ECYP1A2LRRK2 | |
| SCHEMBL218486 | 0.87 | ULK1 (0.42) | ULK1NUDT1KDM4ECYP1A2LRRK2 | |
| SCHEMBL251813 | 0.87 | ULK1 (0.42) | ULK1NUDT1KDM4ECYP1A2LRRK2 | |
| SCHEMBL16015108 | 0.84 | NUDT1 (0.41) | ULK1NUDT1KDM4ECYP1A2LRRK2 | |
| SCHEMBL179470 | 0.84 | NUDT1 (0.41) | ULK1NUDT1KDM4ECYP1A2LRRK2 | |
| SCHEMBL12688252 | 0.84 | ULK1 (0.41) | ULK1NUDT1KDM4ECYP1A2LRRK2 | |
| SCHEMBL18879241 | 0.84 | ULK1 (0.41) | ULK1NUDT1KDM4ECYP1A2LRRK2 | |
| SCHEMBL18708514 | 0.84 | ULK1 (0.41) | ULK1NUDT1KDM4ECYP1A2LRRK2 | |
| SCHEMBL179498 | 0.84 | NUDT1 (0.41) | ULK1NUDT1KDM4ECYP1A2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216982-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | ULK1 214/4885NUDT1 1258/4885CRHR1 4294/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | ULK1 313/4885NUDT1 2412/4885CRHR1 4487/4885 |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | ULK1 213/4885NUDT1 791/4885CRHR1 4755/4885 |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | ULK1 492/4885NUDT1 1478/4885CRHR1 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.